Immunovia have announced that the company’s Lung Cancer collaboration with a global pharmaceutical partner now enters the next stage of the study. The decision to advance was based on the solid progress of the previous study.
In this stage of development, Immunovia will receive fresh blood samples from the pharma partner before the end of 2019 to begin the testing and analysis. The study will be finished in Q2 2020.
The main objective of the collaboration is to generate evidence of IMMray™ platforms performance in predicting response to drug treatments, which would facilitate selection of the right drug for the right patient.
Lung cancer is by far the leading cause of cancer death among both men and women. Each year, more people die of lung cancer than of colon, breast, and prostate cancers combined. About 13% of all new cancers are lung cancers.
This expanded study will also benefit Immunovia’s early detection program, as well as provide an additional data set on the predictive performance capabilities of the IMMray™ platform.
Do you want more of the latest science news straight to your inbox? Become a SelectScience member for free today>>